
Dr Ligibel on Quality-of-Life Gains From the BWEL Weight Loss Program in Breast Cancer
Dr Jennifer Ligibel discusses BWEL quality-of-life results, why weight loss differed across groups, insurance barriers, and GLP-1 counseling.
After surgery, chemotherapy, and radiation, many patients with breast cancer want to know how to feel well, not only how to live longer. In this episode of Targeted Talks, Jennifer A. Ligibel, MD, a professor of medicine at Harvard Medical School and a senior physician in the Breast Oncology Center at Dana-Farber Cancer Institute, discusses quality-of-life results from the phase 3 BWEL trial.
BWEL randomized more than 3000 women with stage II or III breast cancer and overweight or obesity to a two-year, phone-based weight loss program or to health education alone. Its main end point, whether the program lowers the risk of recurrence, is still being followed. The ASCO analysis looked at physical function and other patient-reported outcomes, and Ligibel explains why those results matter to patients after treatment.
She also takes up a harder question: why weight loss was smaller in some groups, including younger women and Black and Hispanic participants, and how a project at Dana-Farber is trying to sort out whether biology, life circumstances, or the design of the program is responsible. She describes why insurers don't yet cover programs like this one, and why survival data could help build the case.
Ligibel then turns to
The conversation follows one thread: if a program helps patients feel better, who is it reaching, and who is it missing?
Related to this article








